论文部分内容阅读
对7例急性髓系白血病(AML)完全缓解期(CR)患者进行自身骨髓移植(ABMT)洽疗,结果7例患者均恢复造血,无1例近期死亡。ABMT后随访情况表明,标危组2例在CR1期移植者已无病生存26及18月,在CR2期移植的2例中1例已超过30月,另1例于移植后9月死于他因,并无白血病复发迹象。3例高危组患者中2例于移植后5月复发,另1例已持续CR5.5月,目前尚在观察中。提示ABMT对标危组AML(CR1及CR2期)患者的疗效优于高危组。
Seven patients with acute myeloid leukemia (AML) with complete remission (CR) were treated with autologous bone marrow transplantation (ABMT). All patients recovered hematopoietic and none of them died recently. The follow-up after ABMT showed that two cases of standard risk group had no disease-free survival in CR1 stage in 26 and 18 months, one case in CR2 stage exceeded 30 months and another died in September after transplantation Because of his, there is no sign of leukemia relapse. Two of the three high-risk patients relapsed after 5 months of transplantation, the other one had been on CR5.5 months and are currently under observation. These results suggest that ABMT is more effective than high-risk group in standard risk AML patients (CR1 and CR2).